Gemcitabine monotherapy
Treatment for Pancreatic Cancer
Typical Dosage: 1000 mg/m2 IV once weekly for 7 weeks, then 1 week rest; subsequent cycles once weekly for 3 weeks, then 1 week rest
Effectiveness
65%
Safety Score
30%
Clinical Trials
65
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
1000 mg/m2 IV once weekly for 7 weeks, then 1 week rest; subsequent cycles once weekly for 3 weeks, then 1 week rest
Time to Effect
1-2 months
Treatment Duration
4-8 months, until progression or unacceptable toxicity
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$18,000
Monitoring:$10,000
Side Effect Mgmt:$15,000
Total Annual:$43,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$15,000/QALY
QALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$573,333
Gemcitabine monotherapy Outcomes
for Pancreatic Cancer
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+8%
Common Side Effects
Neutropenia (Grade 3/4)
+25%
Nausea/Vomiting
+18%
Fatigue
+25%
Flu-like symptoms
+15%
Sources:
Active Clinical Trials
4 active trials recruiting for Gemcitabine monotherapy in Pancreatic Cancer
Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
NCT05841420RECRUITINGPHASE2
98 participants
INTERVENTIONAL
Aalborg, Denmark
Started: Jun 12, 2023
Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine
NCT03854110ACTIVE NOT RECRUITINGPHASE1
64 participants
INTERVENTIONAL
Newport Beach, United States +4 more
Started: Jan 14, 2019
A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer
NCT03301805NOT YET RECRUITINGPHASE2
40 participants
INTERVENTIONAL
Started: Jul 1, 2025
Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
NCT03579836RECRUITINGPHASE1, PHASE2
75 participants
INTERVENTIONAL
Seoul, South Korea
Started: May 14, 2018
Completed Clinical Trials
8 completed trials for Gemcitabine monotherapy in Pancreatic Cancer
Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer
NCT02043288COMPLETEDPHASE3
310 participants
INTERVENTIONAL
Hong Kong, Hong Kong +42 more
Started: Jan 1, 2014
Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)
NCT01808638COMPLETEDPHASE1, PHASE2
29 participants
INTERVENTIONAL
Berlin, Germany +8 more
Started: Mar 1, 2013
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
NCT00902291COMPLETEDPHASE2
205 participants
INTERVENTIONAL
La Jolla, United States +35 more
Started: Apr 1, 2009
EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas
NCT00377936COMPLETEDPHASE2
212 participants
INTERVENTIONAL
Prague, Czechia +2 more
Started: Sep 1, 2005
A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
NCT01833546COMPLETEDPHASE1
20 participants
INTERVENTIONAL
Kashiwa, Japan +1 more
Started: Apr 18, 2013
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
NCT02650804COMPLETEDPHASE2
45 participants
INTERVENTIONAL
Gilbert, United States +11 more
Started: Jul 6, 2016
EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX
NCT03126435COMPLETEDPHASE3
218 participants
INTERVENTIONAL
Corona, United States +67 more
Started: Oct 16, 2018
First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine
NCT02564146COMPLETEDPHASE2
325 participants
INTERVENTIONAL
Weiden, Germany
Started: Dec 1, 2016
Showing 20 of 68 total trials